The Role of Proteomics and Phosphoproteomics in the Discovery of Therapeutic Targets and Biomarkers in Acquired EGFR-TKI-Resistant Non-Small Cell Lung Cancer

The Role of Proteomics and Phosphoproteomics in the Discovery of Therapeutic Targets and Biomarkers in Acquired EGFR-TKI-Resistant Non-Small Cell Lung Cancer

The discovery of potent EGFR-tyrosine kinase inhibitors (EGFR-TKIs) has revolutionized the treatment of EGFR-mutated lung cancer. Despite the fact that EGFR-TKIs have yielded several significant benefits for lung cancer patients, the emergence of resistance to EGFR-TKIs has been a substantial impedi...

Full description

Bibliographic Details
Main Authors:	Sutpirat Moonmuang, Apichat Tantraworasin, Santhasiri Orrapin, Sasimol Udomruk, Busyamas Chewaskulyong, Dumnoensun Pruksakorn, Parunya Chaiyawat
Format:	Article
Language:	English
Published:	MDPI AG 2023-03-01
Series:	International Journal of Molecular Sciences
Subjects:	lung cancer non-small cell lung cancer EGFR-TKI resistance proteomics phosphoproteomics
Online Access:	https://www.mdpi.com/1422-0067/24/5/4827

Similar Items

Clinical Implication of Circulating Tumor Cells Expressing Epithelial Mesenchymal Transition (EMT) and Cancer Stem Cell (CSC) Markers and Their Perspective in HCC: A Systematic Review
by: Santhasiri Orrapin, et al.
Published: (2022-07-01)

Deciphering the Biology of Circulating Tumor Cells through Single-Cell RNA Sequencing: Implications for Precision Medicine in Cancer
by: Santhasiri Orrapin, et al.
Published: (2023-08-01)

Emerging Role of Noncoding RNAs in EGFR TKI-Resistant Lung Cancer
by: Jingwei Li, et al.
Published: (2022-09-01)

Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant
by: Lihao Zhao, et al.
Published: (2019-12-01)

Clinical Developments for the EGFR-TKI Combined with Radiotherapy in Advanced Non-small Cell Lung Cancer
by: Xianan LI, et al.
Published: (2014-04-01)

Histological Transformation after Acquired Resistance to the Third-Generation EGFR-TKI in Patients with Advanced <i>EGFR</i>-Mutant Lung Adenocarcinoma
by: Po-Hsin Lee, et al.
Published: (2022-07-01)

Molecular Mechanism and Progression of Primary Resistance to EGFR-TKI - Analysis of 2 Cases
by: Meirong LIU, et al.
Published: (2019-01-01)

Achievement of Cure with Gefitinib in Advanced Lung Adenocarcinoma Harboring an Activating EGFR Mutation: A Case Report
by: Taiji Kuwata, et al.
Published: (2016-10-01)

Effectiveness of EGFR‐TKI rechallenge immediately after PD‐1 blockade failure
by: Kyoichi Kaira, et al.
Published: (2021-03-01)

Utilisation Patterns and Treatment Outcomes of EGFR-Tyrosine Kinase Inhibitors in EGFR-mutant Advanced Lung Carcinoma in the Pakistani-Asian Population: A Real-world Data Study
by: Kiran Munawar, et al.
Published: (2022-11-01)

Surgical resection of advanced non-small cell lung cancer after a response to EGFR-TKI: presentation of two cases and a literature review
by: Yoko Yamamoto, et al.
Published: (2017-11-01)

IL-22 Confers EGFR-TKI Resistance in NSCLC via the AKT and ERK Signaling Pathways
by: Xiaomeng Wang, et al.
Published: (2019-11-01)

Research Progress of Mechanisms on Intracranial Metastasis of Non-small Cell Lung Cancer after Clinical Benefit from EGFR-TKI
by: Juan JIANG, et al.
Published: (2015-08-01)

Survival analysis of patients with advanced non-small cell lung cancer receiving EGFR-TKI treatment of Yunnan in southwestern China: a real-world study
by: Yanping Lin, et al.
Published: (2023-10-01)

EGFR Targeting TKI-Related Skin Toxicities in a Patient with Darker Skin: A Case Report
by: Arman Zereshkian, et al.
Published: (2022-04-01)

Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma
by: Da Hyun Kang, et al.
Published: (2020-06-01)

Research Progress of HGF/MET Signaling Pathway in EGFR-TKI Resistance  in Non-small Cell Lung Cancer
by: Shilong SONG, et al.
Published: (2014-10-01)

Concurrent use of anlotinib overcomes acquired resistance to EGFR‐TKI in patients with advanced EGFR‐mutant non‐small cell lung cancer
by: Chen Zhang, et al.
Published: (2021-10-01)

Adjuvant EGFR-TKI therapy in resected EGFR-mutation positive non-small cell lung cancer: A real-world study
by: Jun-Feng Liu, et al.
Published: (2023-03-01)

Relationship between ID1 and EGFR-TKI Resistance  in Non-small Cell Lung Cancer
by: Yuchen BAO, et al.
Published: (2016-12-01)

Combining EGFR-TKI With SAHA Overcomes EGFR-TKI-Acquired Resistance by Reducing the Protective Autophagy in Non-Small Cell Lung Cancer
by: Peijun Cao, et al.
Published: (2022-03-01)

Reprogramming of Lipid Metabolism in Lung Cancer: An Overview with Focus on EGFR-Mutated Non-Small Cell Lung Cancer
by: Kamal Eltayeb, et al.
Published: (2022-01-01)

Malignant mesothelioma without asbestos exposure diagnosed during EGFR-TKI treatment of lung adenocarcinoma: A case report
by: Xiaomin Niu, et al.
Published: (2021-01-01)

Switch to EGFR-TKI after upfront platinum doublet induction therapy in non-small cell lung cancer (NSCLC) patients with EGFR (Epidermal Growth Factor Receptor) mutation: A multicentre retrospective study
by: Susana Baptista de Almeida, et al.
Published: (2022-01-01)

EGFR amplification is a putative resistance mechanism for NSCLC–LM patients with TKI therapy and is associated with poor outcome
by: Hainan Yang, et al.
Published: (2022-08-01)

STE029 Overcomes EGFR-TKI Resistance in Human Lung Adenocarcinoma
by: Lin HUANG, et al.
Published: (2022-11-01)

Cosuppression of NF-κB and AICDA Overcomes Acquired EGFR-TKI Resistance in Non-Small Cell Lung Cancer
by: Min-Kyung Yeo, et al.
Published: (2022-06-01)

Glasgow prognostic score predicts efficacy and prognosis in patients with advanced non‐small cell lung cancer receiving EGFR‐TKI treatment
by: Norimitsu Kasahara, et al.
Published: (2020-08-01)

Radiolabeled EGFR TKI as predictive imaging biomarkers in NSCLC patients – an overview
by: Eveline Van De Stadt, et al.
Published: (2022-10-01)

Rechallenge with EGFR-TKI after failure of immunotherapy is considered an effective treatment for advanced lung adenocarcinoma patients with EGFR exon 19 deletion: a case report
by: Shubin Chen, et al.
Published: (2023-06-01)

Case report: Response to Savolitinib/EGFR-TKI combination in NSCLC patients harboring concurrent primary MET amplification/overexpression and EGFR mutation
by: Xiaolin Ren, et al.
Published: (2024-02-01)

The Prediction Of Epidermal Growth Factor Receptor Mutation And Prognosis Of EGFR Tyrosine Kinase Inhibitor By Serum Ferritin In Advanced NSCLC
by: Wu Z, et al.
Published: (2019-10-01)

Chromosomal Copy Number Variation Predicts EGFR-TKI Response and Prognosis for Patients with Non-Small Cell Lung Cancer
by: He H, et al.
Published: (2023-09-01)

Lung adenocarcinoma presents with diffuse bone metastasis
by: Jinye Mi, et al.
Published: (2021-10-01)

Potential Therapeutic Strategy for EGFR-Mutant Lung Cancer With Concomitant EML4-ALK Rearrangement—Combination of EGFR Tyrosine Kinase Inhibitors and ALK Inhibitors
by: Ming-Hung Huang, PhD, et al.
Published: (2022-11-01)

Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study
by: Chiao-En Wu, et al.
Published: (2021-07-01)

RNA Structural Dynamics Modulate EGFR-TKI Resistance Through Controlling YRDC Translation in NSCLC Cells
by: Boyang Shi, et al.
Published: (2023-08-01)

Analyze and Identify Peiminine Target EGFR Improve Lung Function and Alleviate Pulmonary Fibrosis to Prevent Exacerbation of Chronic Obstructive Pulmonary Disease by Phosphoproteomics Analysis
by: Xiaoyao Ma, et al.
Published: (2019-07-01)

Overlap time is an independent risk factor of radiation pneumonitis for patients treated with simultaneous EGFR-TKI and thoracic radiotherapy
by: Wenxiao Jia, et al.
Published: (2021-02-01)

Expression of ARL4C in Non-small Cell Lung Cancer and Its Role in EGFR-TKI Resistance
by: CHEN Zeng, et al.
Published: (2020-07-01)